How a combined qual quant approach provided our client with integral insights for continued product development in the HIV space
Our client was looking to develop novel HIV prevention products, and wanted to explore different formulation options.
They wanted to learn both the reactions to the novel formulations as well as the impact of out-of-pocket (OOP) costs. Research was required to explore physician and consumer interest and gauge the impact of these developments on new and existing products.
Are dual ARVs the new frontier in a maturing HIV market?
Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.
Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.
Our latest HIV market snapshot, reveals that 2 in 3 patients are currently treated with an STR (Single-tablet regimen) and more than half are treated with InSTIs (Integrase strand transfer inhibitors). Therapy Watch HIV patient data is collected bi-monthly from a panel of 225 physicians across the main 5 EU markets.
How buyer insights supported the development of an effective market strategy
Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to understand how new medicines are added to the guidelines and how they are evaluated and funded. They also needed to gain an understanding of stakeholders’ reactions to their product, the drivers and barriers to use and expectations regarding pricing.
Investigating factors affecting time to initiation of hepatitis treatment
Following the Viral Hepatitis Congress 2014 in Germany where Darren Kottler presented a poster presentation, he shares some of the factors affecting time from diagnosis to initiation of therapy in hepatitis patients.
By analysing the factors that lead to a patient to be treated for hepatitis, Therapy Watch data can illustrate the key elements of the patient’s condition that lead to one patient being treated sooner than another.